← Leaderboards
Harold A Chapman
University Of California, San Francisco
$29,865,601
Attributed
$41,482,676
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$41,482,676 · 13
By mechanism
R01$11,903,289 · 5
U01$11,248,729 · 2
R35$5,785,426 · 1
R33$5,723,087 · 1
R37$3,808,326 · 1
P01$2,521,398 · 1
Top collaborators
- Darrell N. Kotton7 shared
- Jason Randall Rock7 shared
- Pao-Tien Chuang5 shared
- Matthew F Krummel5 shared
- Fernando J Martinez5 shared
- Catherine A Spino5 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Hyunil Jo$2,065,344
- Aparna Bala Sundaram$3,043,645
- Terumi Kohwi-Shigematsu$22,399,034
- Kai-Hui Sun$104,704
- Matthew F Krummel$32,506,768
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungIn VivoCellsPathway InteractionsSignal TransductionAlveolarEpithelialEpithelial CellsBasePulmonary FibrosisProgramsTissuesInjuryLeadLung InjuryFibroblastsFibrosisIntegrinsComplexProgenitorStem CellsType Ii Epithelial Receptor CellLung DiseasesMolecular
Grant awards (72)
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients$1,763,207
R33 · FY2025 · HL
Program to promote lung regeneration and block fibrosis$966,372
R35 · FY2025 · HL · contact PI
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients$1,758,766
R33 · FY2024 · HL
Program to promote lung regeneration and block fibrosis$947,046
R35 · FY2024 · HL · contact PI
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients$48,139
R33 · FY2024 · HL
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients$2,152,975
R33 · FY2023 · HL
Program to promote lung regeneration and block fibrosis$968,766
R35 · FY2023 · HL · contact PI
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage$1,186,445
U01 · FY2022 · HL · contact PI
Program to promote lung regeneration and block fibrosis$968,766
R35 · FY2022 · HL · contact PI
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients$453,796
R61 · FY2022 · HL
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage$1,202,147
U01 · FY2021 · HL · contact PI
Program to promote lung regeneration and block fibrosis$968,976
R35 · FY2021 · HL · contact PI
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage$1,216,653
U01 · FY2020 · HL · contact PI
Program to promote lung regeneration and block fibrosis$965,500
R35 · FY2020 · HL · contact PI
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage$1,233,079
U01 · FY2019 · HL · contact PI
LOXL-2 dependent blockade of TGF Beta1 signaling and lung fibrosis$591,304
R01 · FY2019 · HL · contact PI
Epithelial Stem/Progenitor Cells in Repair of the Injured Lung$496,755
R01 · FY2019 · HL · contact PI
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage$1,249,427
U01 · FY2018 · HL · contact PI
Epithelial Stem/Progenitor Cells in Repair of the Injured Lung$496,755
R01 · FY2018 · HL · contact PI
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage$948,264
U01 · FY2017 · HL · contact PI
Epithelial Stem/Progenitor Cells in Repair of the Injured Lung$496,755
R01 · FY2017 · HL · contact PI
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage$1,015,063
U01 · FY2016 · HL · contact PI
Inhibitors of Epithelial TGFB signaling and EMT/Sheppard$843,421
P01 · FY2016 · HL · contact PI
Epithelial Progenitor Cells in Lung Repair and Regeneration$616,676
U01 · FY2016 · HL · contact PI
Epithelial Stem/Progenitor Cells in Repair of the Injured Lung$496,336
R01 · FY2016 · HL · contact PI
Epithelial Progenitor Cells in Lung Repair and Regeneration$622,333
U01 · FY2015 · HL · contact PI
Epithelial Stem/Progenitor Cells in Repair of the Injured Lung$495,915
R01 · FY2015 · HL · contact PI
Inhibitors of Epithelial TGFB signaling and EMT/Sheppard$436,071
P01 · FY2015 · HL · contact PI
Epithelial Progenitor Cells in Lung Repair and Regeneration$633,647
U01 · FY2014 · HL · contact PI
Inhibitors of Epithelial TGFB signaling and EMT/Sheppard$399,897
P01 · FY2014 · HL · contact PI
Epithelial Mesenchymal Transition in Pulmonary Fibrosis$374,740
R01 · FY2014 · HL · contact PI
Epithelial Progenitor Cells in Lung Repair and Regeneration$629,745
U01 · FY2013 · HL · contact PI
Inhibitors of Epithelial TGFB signaling and EMT/Sheppard$401,587
P01 · FY2013 · HL · contact PI
Epithelial Mesenchymal Transition in Pulmonary Fibrosis$364,033
R01 · FY2013 · HL · contact PI
Epithelial Progenitor Cells in Lung Repair and Regeneration$695,250
U01 · FY2012 · HL · contact PI
Inhibitors of Epithelial TGFB signaling and EMT/Sheppard$440,422
P01 · FY2012 · HL · contact PI
Epithelial Mesenchymal Transition in Pulmonary Fibrosis$382,388
R01 · FY2012 · HL · contact PI
Epithelial Mesenchymal Transition in Pulmonary Fibrosis$386,250
R01 · FY2011 · HL · contact PI
Urokinase Receptor Integrin Interactions in Lung Cancer$284,744
R01 · FY2011 · CA · contact PI
Role of Elastolytic Cathepsins in Emphysema$452,346
R37 · FY2010 · HL · contact PI
Epithelial Mesenchymal Transition in Pulmonary Fibrosis$386,250
R01 · FY2010 · HL · contact PI
Urokinase Receptor Integrin Interactions in Lung Cancer$293,550
R01 · FY2010 · CA · contact PI
Role of Elastolytic Cathepsins in Emphysema$448,881
R37 · FY2009 · HL · contact PI
Regulation of Integrin Function$367,766
R01 · FY2009 · HL · contact PI
Urokinase Receptor Integrin Interactions in Lung Cancer$293,550
R01 · FY2009 · CA · contact PI
Identification, Isolation, and Reprogramming Alveolar Epithelial Progenitor Cells$38,625
R03 · FY2009 · HL · contact PI
Role of Elastolytic Cathepsins in Emphysema$428,082
R37 · FY2008 · HL · contact PI
Regulation of Integrin Function$367,766
R01 · FY2008 · HL · contact PI
Urokinase Receptor Integrin Interactions in Lung Cancer$293,471
R01 · FY2008 · CA · contact PI
Role of Elastolytic Cathepsins in Emphysema$423,045
R37 · FY2007 · HL · contact PI
Regulation of Integrin Function$367,766
R01 · FY2007 · HL · contact PI
Cysteine Proteases in MHC Class II Antigen Presentation$323,212
R01 · FY2007 · HL · contact PI
Urokinase Receptor Integrin Interactions in Lung Cancer$292,600
R01 · FY2007 · CA · contact PI
Role of Elastolytic Cathepsins in Emphysema$421,666
R37 · FY2006 · HL · contact PI
Regulation of Integrin Function$378,750
R01 · FY2006 · HL · contact PI
Cysteine Proteases in MHC Class II Antigen Presentation$332,865
R01 · FY2006 · HL · contact PI
Cysteine Proteases in MHC Class II Antigen Presentation$340,875
R01 · FY2005 · HL
Role of Elastolytic Cathepsins in Emphysema$336,867
R37 · FY2005 · HL
Cysteine Proteases in MHC Class II Antigen Presentation$340,875
R01 · FY2004 · HL
Role of Elastolytic Cathepsins in Emphysema$323,664
R37 · FY2004 · HL
REGULATION OF INTEGRIN FUNCTION$312,333
R01 · FY2004 · HL
Cysteine Proteases in MHC Class II Antigen Presentation$339,562
R01 · FY2003 · HL
Role of Elastolytic Cathepsins in Emphysema$316,675
R37 · FY2003 · HL
REGULATION OF INTEGRIN FUNCTION$303,464
R01 · FY2003 · HL
Role of Elastolytic Cathepsins in Emphysema$316,675
R37 · FY2002 · HL
REGULATION OF INTEGRIN FUNCTION$294,622
R01 · FY2002 · HL
CYSTEINE PROTEASES IN MHC CLASS II ANTIGEN PRESENTATION$286,892
R01 · FY2002 · HL
Role of Elastolytic Cathepsins in Emphysema$340,425
R37 · FY2001 · HL
REGULATION OF INTEGRIN FUNCTION$286,042
R01 · FY2001 · HL
CYSTEINE PROTEASES IN MHC CLASS II ANTIGEN PRESENTATION$281,382
R01 · FY2001 · HL
REGULATION OF INTEGRIN FUNCTION$277,709
R01 · FY2000 · HL
CYSTEINE PROTEASES IN MHC CLASS II ANTIGEN PRESENTATION$276,012
R01 · FY2000 · HL